Flushing, New York Clinical Trials

A listing of Flushing, New York clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 360 clinical trials
Heart Transplantation Using Normothermic Regional Perfusion Donation After Circulatory Death

Normothermic regional perfusion (NRP) utilizes Extracorporeal Membrane Oxygenation (ECMO) or cardiopulmonary bypass to reperfuse the heart and other organs in situ after isolation and ligation of the cerebral vessels. In situ resuscitation of the heart has the added advantage of allowing full hemodynamic and echocardiographic assessment of the donor heart …

heart transplantation
NYU Langone Health
 (8.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs

The investigators are doing this study to find out whether lowering the dose of postoperative radiation therapy and targeting a smaller area of tissue for treatment is as effective as the standard dose and volume of radiation therapy to control soft tissue sarcoma after surgery. They also want to find …

serum pregnancy test
sarcoma
primary tumor
sarcoma of the extremity
soft tissue sarcoma
Memorial Sloan Kettering Cancer Center
 (6.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +6 other locations
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

refractory malignant glioma
antineoplastic agents
pediatric
MRI
blood transfusion
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
 (7.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +82 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

multiple meningiomas
neurofibroma
neutrophil count
nf2 gene
cataract
Memorial Sloan Kettering Cancer Center (Site 210)
 (6.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +16 other locations
Targeted Fortification of Donor Breast Milk in Preterm Infants

This study is a randomized controlled trial comparing standard fortification of donor breast milk to targeted fortification of donor breast milk in preterm infants. The purpose of the study is to determine if there is a benefit to target fortifying donor breast milk in the preterm population. The investigators hypothesize …

Columbia University Medical Center/ New York - Presbyterian
 (7.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

solid tumor
ki-ras
kras
kras g12c mutation
metastatic malignant solid tumor
Memorial Sloan Kettering Cancer Center
 (6.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +7 other locations
Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.

serum testosterone
prostate cancer
adenocarcinoma of prostate
metastatic hormone refractory prostate cancer
androgen suppression
Memorial Sloan-Kettering Cancer Center
 (6.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +5 other locations
ctgov trial 2

    dddd

Test Site
 (8.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

multiple myeloma
daratumumab
immunotherapeutic agent
refractory multiple myeloma
lenalidomide
Investigational Site Number 8400001
 (5.9 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +7 other locations
Test Campaign Performance Report  

Test Campaign Performance Report

Site Test A
 (9.3 away)
  • 0 views
  • 19 Feb, 2024
  • +2 other locations